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ABTRACT 
Ligand-induced activation of Exchange Protein Activated by cAMP-1 (EPAC1) is implicated in 
numerous physiological and pathological processes, including cardiac fibrosis where changes in 
EPAC1 expression have been detected.  However, little is known about how EPAC1 expression 
is regulated. Therefore, we investigated regulation of EPAC1 expression by cAMP in cardiac 
fibroblasts. 
Elevation of cAMP using forskolin, cAMP-analogues or adenosine A2B-receptor activation 
significantly reduced EPAC1 mRNA and protein levels and inhibited formation of F-actin stress 
fibres. Inhibition of actin polymerisation with cytochalasin-D, latrunculin-B or the ROCK 
inhibitor, Y-27632, mimicked effects of cAMP on EPAC1 mRNA and protein levels. Elevated 
cAMP also inhibited activity of an EPAC1 promoter-reporter gene, which contained a consensus 
binding element for TEAD, which is a target for inhibition by cAMP. Inhibition of TEAD activity 
using siRNA-silencing of its co-factors YAP and TAZ, expression of dominant-negative TEAD 
or treatment with YAP-TEAD inhibitors, significantly inhibited EPAC1 expression. However, 
whereas expression of constitutively-active YAP completely reversed forskolin inhibition of 
EPAC1-promoter activity it did not rescue EPAC1 mRNA levels. Chromatin-
immunoprecipitation detected a significant reduction in histone3-lysine27-acetylation at the 
EPAC1 proximal promoter in response to forskolin stimulation. HDAC1/3 inhibition partially 
reversed forskolin inhibition of EPAC1 expression, which was completely rescued by 
simultaneously expressing constitutively active YAP. 
 
Taken together, these data demonstrate that cAMP downregulates EPAC1 gene expression via 
disrupting the actin cytoskeleton, which inhibits YAP/TAZ-TEAD activity in concert with 
HDAC-mediated histone deacetylation at the EPAC1 proximal promoter. This represents a novel 
negative feedback mechanism controlling EPAC1 levels in response to cAMP elevation. 
 
Keywords: cAMP, EPAC, YAP, TEAD, HDAC, ACTIN 
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ABBREVIATIONS 
α-SMA Alpha Smooth Muscle Cell Actin 
cAMP  3'5'- cyclic adenosine monophosphate 
EC  Endothelial cell 
EPAC1 Exchange Protein Activated by cAMP  
HDAC  Histone Deacetylase 
TAZ  Transcriptional Co-Activator With PDZ-Binding Motif 
TEAD  TEA Domain Transcription Factor 1 
YAP  YES-Associated Protein 
 
INTRODUCTION 
Exchange protein activate by cAMP-1 (EPAC1) is a cAMP-dependent guanine nucleotide 
exchange factor (GEF) that is implicated in numerous physiological and pathological processes 
[1, 2]. The development of EPAC-selective cAMP analogues such as 8-(4-chlorophenylthio)-2′-
O-methyl-cAMP[3] has helped identify many important physiological functions of EPAC activity 
in cardiac cells, including regulation of cardiac fibroblast proliferation[4] and migration[5], 
regulation of vascular permeability[6-8], regulation of myocyte calcium signalling[9], regulation 
of myocyte contraction[10], regulation of inflammation[11, 12] and hypertrophy[13] and cardiac 
fibrosis [14].  Two isoforms of EPAC have been identified, EPAC1 and EPAC2 that respectively 
contain one or two cyclic AMP binding domains (CBD), which are homologous to those present 
in cAMP-dependent protein kinase (PKA) regulatory subunits, and allow activation of GEF 
activity in response to physiological levels of intracellular cAMP [15].  EPAC1 is more widely 
expressed than EPAC2, being ubiquitously expressed in cardiac cells [5, 16].   
Cardiac fibroblasts (CFs) are the main non-myocyte cell type in the heart[17]. They occupy the 
myocardial interstitium [18], performing a number of important functions that maintain normal 
myocardial homeostasis, including regulation of myocardial extracellular matrix (ECM) and 
myocardial integrity as well as functioning as mechano-electric transducers [19]. In response to a 
range of signals, including angiotensin II and TGF-, CFs trans-differentiate into myofibroblasts, 
characterised by increases in alpha-smooth muscle actin (α-SMA) expression, proliferation, 
migration and collagen synthesis[20]. The transition to this myofibroblast phenotype promotes 
myocardial healing after cardiac injury [21, 22]. However, aberrant or excessive ECM deposition 
and myofibroblast proliferation has been implicated in the development of maladaptive fibrosis, 
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which increases the stiffness of the myocardium, impairs cardiac function and promotes the 
development of heart failure[20, 23].  
 
Several lines of evidence suggest that signals that elevate intracellular cAMP, such as the 
extracellular nucleoside adenosine, have been shown to have many anti-fibrotic properties[24] , 
including inhibition of CF proliferation[25] and collagen synthesis[26]. For example, in a rat 
model of myocardial infarction, agents that elevate adenosine levels reduced tissue scar 
formation [27]. These anti-fibrotic properties are mediated via the Gs coupled adenosine A2B 
receptor, which activates adenylate cyclase (AC) and increases intracellular cAMP levels. 
Silencing of the adenosine A2B receptor increases CF proliferation[28] and collagen synthesis[29] 
whereas its overexpression has the opposite effects[28]. These protective effects of adenosine are 
mediated by increases in intracellular cAMP and activation of EPAC1. For example, over 
expression of AC or its activation with forskolin inhibits TGF-β- or angiotensin-II induced 
myofibroblast differentiation, collagen synthesis and proliferation in CF [30-32]. Direct activation 
of EPAC1, with the selective EPAC agonist, 8-pCPT-2'-O-Me-cAMP or via EPAC1 over 
expression attenuates angiotensin-II- and TGF--induced CF proliferation, migration and collagen 
synthesis in vitro[14, 26, 33] and reduces cardiac fibrosis in a canine model of ventricular 
tachypacing[14]. Furthermore, pharmacological inhibition of EPAC activity with ESI-09 reverses 
the inhibitory effects of adenosine on angiotensin-II or endothelin-1 (ET1) induced collagen 
synthesis and myofibroblast differentiation [20, 34]. Taken together, these data suggest that 
activation of EPAC1 in response to elevated cAMP inhibits cardiac fibrosis. 
 
Importantly, several studies have demonstrated that EPAC1 levels can be modulated in response 
to various physiological and pathological stimuli. For example, TGF- and angiotensin II both 
promote the down regulation of EPAC1 mRNA and protein expression in cardiac fibroblasts in 
vitro [5, 33].  EPAC1 mRNA and protein levels are also reduced in vivo in a rat myocardial 
infarction model and a canine ventricular tachypacing model of heart failure [14, 33]. Here we 
characterise the regulation of EPAC1 gene expression in response to cAMP elevation. We describe 
a novel negative feedback loop by which EPAC1 and PKA activation by cAMP reduces EPAC1 
expression by inhibiting TEA Domain Family Transcription Factors (TEAD) activity and histone-
H3 lysine-27-acetylation of the EPAC1 proximal promoter. 
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METHODS 
Materials: All chemicals were obtained from Sigma unless otherwise stated. Antibodies to EPAC1 
(#4155) were from Cell Signalling Technologies. Antibodies to GAPDH (#MAB374) were from 
Merck-Millipore. Forskolin and dibutyryl-cAMP was purchased from Sigma Aldrich. BAY60-
6583 was purchased from Cambridge Bioscience (U.K.). 6-BNZ-cAMP-AM [35], a cell 
permeable selective  PKA agonist, and 8-pCPT-2'-O-Me-cAMP-AM (8-CPT-AM), a cell 
permeable selective  EPAC super-agonist [36], were purchased from Biolog (Germany) and used 
at 20 µM in accordance with the manufacturers recommendations.  
Cardiac fibroblast culture: All experiments were performed using different batches of cells that 
were prepared from different animals. Male Sprague Dawley rat pups were killed by cervical 
dislocation in accordance with Directive 2010/63/EU of the European Parliament, under schedule 
1 of the United Kingdom Home Office Animal Scientific Procedures Act 1986 and performed in 
accordance with guidelines, regulations and approval of the University of Bristol. Approval was 
granted by the University of Bristol ethical review board. Cultures of rat cardiac fibroblasts were 
prepared as previously described [37]. Briefly, hearts from 2- to 3-day-old rats were digested with 
four cycles of incubation in 0.1% trypsin containing 0.02% EDTA in PBS. Digestion was stopped 
by the addition of foetal calf serum (FCS) to 20%. The dispersed cells were resuspended in MEM 
supplemented with 10% FCS, 100 µg/mL streptomycin, and 100 U/mL penicillin and plated for 1 
hour to allow fibroblasts to adhere. The unattached myocytes were removed with two washes in 
PBS. Cardiac fibroblasts were cultured in Advanced DMEM/F12 supplemented with 100 µg/ml 
streptomycin and 100 U/mL penicillin, 10% FCS and 2 mM L-glutamine.  H9C2 cardiomyocyte 
cells were cultured in DMEM supplemented with 100 µg/ml streptomycin and 100 U/mL 
penicillin, 10% FCS and 2 mM L-glutamine. Stimulations were performed in serum free DMEM 
unless otherwise stated. Cells were serum-starved for 18 hours or 4 hours, as indicated in figure 
legends.  
Plasmids and adenoviral vectors: EPAC1 promoter fragments were generated by PCR using 
KOD polymerase from human genomic DNA. The location of the 800 bp promoter fragment is 
chr12:48152755-48153554 (Hg19).  The proximal TEAD element (5’-GCATTCCTC-3’) was 
mutated to (5’-GCgTgtCTC-3’) by PCR with a reverse primer incorporating the mutated element. 
Promoter fragments were cloned into the Nhe1 sites of the secreted nano-luciferase reporter gene 
plasmid pNL3.3[secNluc/minP] (Promega).  The synthetic TEAD luciferase reporter plasmid 
containing eight copies of a TEAD binding element has been described previously [38] and was 
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obtained from Addgene (plasmid #34615). Luciferase reporter plasmid containing the minimal 
TNT promoter was generated by BglII and Kpn1 digestion of the TEAD-LUC vector to remove 
the eight TEAD elements, leaving just the minimal TNT-promoter. Plasmid expressing dominant-
negative TEAD in which the YAP-binding domain of TEAD is replaced with the repressor domain 
of Engrailed (TEAD-ENRD) was a gift from Prof Domenico Flagiello (University of Paris Diderot) 
and has been described previously [39]. Adenovirus vectors expressing constitutively active YAP 
(YAPS127A), constitutively active TAZ (TAZ5SA) or control virus lacking a transgene (Ad:Control) 
have been described previously [40]. Cardiac fibroblasts were infected with 1x107 pfu/mL of 
recombinant adenovirus for 18 hours.  
Quantitative RT-PCR and Western blotting: Quantification of mRNA and protein levels was 
performed by RT-qPCR and western blotting respectively, as described previously [41]. Total 
RNA was extracted using Ambion Pure-Link kits (Thermo Fisher) and was reverse transcribed 
using the QuantiTect RT kit (Qiagen) and random primers. Quantitative PCR was performed using 
Roche SYBR Green and a Qiagen Roto-Gene qPCR machine (20’@95oC;20’@62oC;20’@72oC). 
Primer sequences are described in Supplement Table 1. Western blots were performed using a 
Mini-Protean II system. Proteins were transferred to PVDF membrane using wet transfer and 
detected using ECL (Luminata Forte, Millipore) and a digital ChemiDoc imaging system (Bio-
Rad).  
Transient transfection and reporter gene assays: EPAC1 promoter activity was determined by 
quantifying the secreted nano-luciferase reporter activity in cells transfected with EPAC1-NLUC.  
Plasmid transfection was performed by electroporation of 1x106 cardiac fibroblasts with 5 μg of 
plasmid DNA using an Amaxa Nucleofector-1.5 (program A-024). For gene silencing, cells were 
transfected with 100 pmoles of Silencer Select siRNA (Life Technologies) targeting YAP1 
(ID:s170198 and ID:s170200) or TAZ/WWTR1 (ID: s148961) using the standard Nucleofector 
program A-024.  Cells were stimulated with the indicated agents 24 hours post transfection. The 
next day cell lysates were assayed for firefly luciferase activity and cell culture media assayed for 
secreted nano-luciferase. Firefly luciferase was quantified using the luciferase assay system 
(Promega) and secreted nanoluciferase activity assayed using the NanoGlo assay system 
(Promega) according to the manufactures instructions using Glomax Discover luminometer 
(Promega). 
Electromobility shift assays: Electromobility shift assays (EMSA) were performed using the 
Lightshift EMSA kit (Thermo Fisher), according to the manufacturer’s instructions. Nuclear 
extracts from 5x106 control or pRK-myc-TEAD1 (Addgene #33109) transfected cells were 
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prepared using the NE-PER nuclear extraction kit (Thermo Fisher). Double stranded 5’ 
biotinylated probes corresponding to the wild-type or TEAD element mutant human EPAC1 
promoter TEAD element (Wild-type sense 5’-Biotin- TTC CCC TAC GCA TTC CTC TAC CGT 
AA-3’; Wild-type antisense 5’-Biotin-TTA CGG TAG AGG AAT GCG TAG GGG AA-3’; 
TEAD-mutant sense 5’-Biotin- TTC CCC TAC GCg Tgt CTC TAC CGT AA-5’ and TEAD 
mutant antisense 5’-Biotin-TTA CGG TAG Aga cAc GCG TAG GGG AA-3’) were synthesised 
by Sigma Aldrich. 20 fmol of double stranded DNA oligo was used in 20 uL binding reactions 
according to the Lightshift assay kit protocol. DNA complexes were resolved on 5% non-
denaturing polyacrylamide/0.5xTBE gels at 100V. Oligonucleotides were transferred to Hybond-
N nylon membrane (Amersham) in 0.5 x TBE at 400 mA for 1 hour at 4oC. Oligonucleotides were 
detected using the Lightshift kit Extravidin-HRP detection system. 
Chromatin Immunoprecipitation assays: Cardiac fibroblasts (approximately 8x106 cells) were 
washed in PBS and fixed in 11% formaldehyde in PBS for eight minutes at room temperature. 
Formaldehyde was quenched by addition of glycine to a final concentration of 250 mM. Chromatin 
was prepared using the iDeal ChIP-qPCRkit (Diagenode) according to the manufacturer’s 
instructions. Chromatin was sheared using 2.5 cycles (10 rounds of 30 seconds on and 30 seconds 
off per cycles) of sonication in a Bioruptor sonicator (Diagenode). Sheared chromatin was 
immunoprecipitated overnight at 4oC with either 1 µg of anti-H3K27Ac antibody (#C15410174; 
Diagenode) or an equal amount of rabbit non-immune IgG (#C15410206; Diagenode) according 
to the iDeal Chip-qPCR kit instructions. Following washing and elution, immunoprecipitated 
DNA was quantified using qPCR with primers (Forward 5’- CCT CTG GAC TTG GAC TGG 
TCA TGC-3’ and Reverse 5’- GCC GAA TTC CAG CCA GAA CTG AGA-3’) amplifying the 
proximal EPAC located at chr7:139254198-139254358 (rn6) 
RAP1GTP activity assays: Levels of cellular RAP1GTP were quantified using the Cell Signalling 
Active Rap1 detection kit according to the manufacturer’s instructions. Briefly, cells were seeded 
at 5x106 cells/well in 6 well plates. Cells were pre-treated with 25 µM forskolin for 24 hours, as 
indicated before an acute stimulation the following day. RAP1GTP present in cell lysates was 
bound to 20 µg of GST-RAL-GDS protein and affinity isolated using glutathione resin. Following 
washing to remove non-specifically bound protein, specifically bound RAP1GTP as eluted in 
Laemmli sample buffer and analysed for RAP1 protein levels by Western blotting. 
F-Actin:G-Actin ratio assay: F:G actin ratio was quantified essentially as previously described 
[42]. Following treatment, G-actin was extracted in G-actin extraction buffer (PBS, 10% 
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glycerol, 0.1% triton X-100, 1 mM ATP and complete protease inhibitor) and incubated for 
5 min at room temperature with slight agitation. Samples were centrifuged at 15,000 g at 4 °C 
for 5 min. The supernatant (soluble G-actin) was collected. Titon-X-100 insoluble material (F-
actin) remaining in the wells and pelleted from the soluble fraction was lysed in reducing 
Laemmli SDS sample buffer. Samples were analysed by western blotting using a β-actin 
specific antibody (Sigma). 
Image Analysis: Immunofluorescent micrograph images were quantified using CellProfiler [43]. 
Nuclei were identified from DAPI images using the “IdentifyPrimaryObjects” module. 
Cytoplasmic regions were derived by expanding nuclei (“ExpandOrShrinkObjects” module) and 
subtracting the original nuclei (“IdentifyTertiaryObjects” module), nuclear regions were derived 
by shrinking original nuclei (“ExpandOrShrinkObjects” module). YAP intensity (488 channel) 
was measured in cytoplasm and nuclei using the “MeasureObjectIntensity” module. Cell area was 
calculated from phase contrast images using ImageJ[44]. 
Statistical Analysis: After testing data sets for normality, statistical analysis was performed using 
two-way ANOVA, one-way ANOVA with Student-Newman-Keul’s post-test or where 
appropriate a paired Student’s t-test, as indicated. * indicates p<0.05, ** indicates p<0.01, *** 
indicates p<0.001. 
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RESULTS 
Adenosine A2B activation and elevated cAMP inhibits EPAC1 expression in cardiac fibroblasts 
Activation of the adenosine A2B-receptor elevates intracellular cAMP levels and has anti-fibrotic 
effects in cardiac fibroblasts [29]. We initially stimulated cardiac fibroblasts with the adenosine 
A2B receptor agonist BAY60-6583 (at 5 µg/mL as previously described [45]) and quantified 
EPAC1 mRNA and protein levels at early timepoints (i.e. less than 8 hours) to identify direct 
effects on EPAC1 levels and avoid confounding effects of secondary signalling mechanisms. We 
focused on the regulation of EPAC1 as we were unable to detect EPAC2 protein expression in 
cardiac fibroblasts by Western blotting (Supplement Figure 1), consistent with previous 
observations [33]. Stimulation with BAY60-6583 significantly reduced EPAC1 mRNA levels 
after 2 and 8 hours (Figure 1A). Levels of EPAC1 pre-spliced RNA, a surrogate measure of 
EPAC1 transcriptional rate[46], were similarly reduced at 2 and 8 hours (Figure 1A). Levels of 
the housekeeping gene 36B4 were unaffected. BAY60-6583 also significantly reduced levels of 
EPAC1 protein after 2, 4, 6 and 8 hours, with maximal inhibition at the 8-hour time-point (Figure 
1B). Similar down regulation of EPAC1 mRNA was detected in human cardiac fibroblasts, 
stimulated with BAY-60-6583 (Supplementary Figure 2A). We next tested if elevating 
intracellular cAMP levels with the adenylate cyclase agonist forskolin (at 25 µM as previously 
described [42]) or the cAMP analogue, dibutyryl-cAMP (at 200 µM as previously described [41]) 
also inhibited EPAC1 expression. Stimulation with forskolin significantly inhibited EPAC1 
mRNA and pre-spliced EPAC1 RNA at 2 and 8 hours without affecting 36B4 mRNA levels 
(Figure 1C). Forskolin stimulation also resulted in time dependent inhibition of EPAC1 protein 
levels, with maximal inhibition after 8 hours (Figure 1D). Stimulation of human CF with forskolin 
also resulted in the downregulation of the protein and mRNA levels of EPAC1 after 8 hours 
(Supplementary Figure 2B). In a similar manner, stimulation with dibutyryl-cAMP also 
significantly reduced EPAC1 mRNA and pre-spliced EPAC1 mRNA at 2 and 8 hours (Figure 1E) 
and EPAC1 protein levels (Figure 1F). Elevated cAMP can activate both PKA and EPAC. We 
therefore tested whether PKA or EPAC activity was involved in inhibition of EPAC1 expression 
in cardiac fibroblasts. We initially used the PKA and EPAC selective pharmacological inhibitors 
H89 and ESI-09{Almahariq, 2013 #3608}. Treatment with H89 or ESI-09 significantly reversed 
the forskolin-induced reduction in EPAC1 mRNA and pre-spliced EPAC1 mRNA levels (Figure 
2A), suggesting involvement of both PKA and EPAC activity in the regulation of EPAC1 mRNA 
levels. To further test the role of PKA and EPAC activity, we stimulated cells with the PKA 
selective agonist 6-BNZ-cAMP-AM or the non-cyclic EPAC selective agonist I-942 [47]. 
Stimulation with 6-BNZ-cAMP-AM or I-942 alone resulted in a significant down regulation of 
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EPAC1 mRNA and pre-spliced EPAC mRNA without affecting levels of 36B4 (Figure 2B). A 
combination of I-942 plus 6-BNZ-cAMP-AM acted additively to suppress EPAC1 mRNA and 
pre-spliced RNA levels. To further test the role of EPAC activation in the regulation of EPAC1 
mRNA levels, we stimulated cells with the cell permeable EPAC selective cAMP analogue 8-
pCPT-2'-O-Me-cAMP-AM  (abbreviated to 8-CPT-AM) alone or in combination with the PKA 
selective agonist 6-BNZ-cAMP-AM. Stimulation with 8-pCPT-2'-O-Me-cAMP-AM or 6-BNZ-
cAMP-AM alone significantly down regulated EPAC1 mRNA and pre-spliced EPAC mRNA 
without affecting levels of 36B4 (Figure 2C). A combination of 6-BNZ-cAMP-AM plus 8-pCPT-
2'-O-Me-cAMP-AM acted additively to suppress EPAC1 mRNA and pre-spliced RNA.  EPAC1 
protein levels were significantly inhibited in response to 6-BNZ-cAMP-AM or a combination of 
6-BNZ-cAMP plus 8-pCPT-2'-O-Me-cAMP-AM but not by 8-pCPT-2'-O-Me-cAMP-AM alone 
(Figure 2D). 
 
Inhibition of EPAC1 expression by cAMP is associated with actin-cytoskeleton remodelling and 
changes in cell morphology 
Elevated levels of cAMP have previously been shown to modulate cell morphology and actin 
polymerisation in several cell types {Bond, 2008 #1738; Duggirala, 2015 #3210;Hewer, 2011 
#1841; Kimura, 2016 #3418; Wu, 2006 #1597; Pelletier, 2005 #2641}, and this has been 
functionally linked to cAMP-induced changes in cell behaviour. This typically occurs as a result 
of cAMP-mediated inhibition of RhoGTPase activity [48]. We noted that inhibition of EPAC1 
expression by cAMP-elevating stimuli in cardiac fibroblasts was associated with a reduction in 
cell spreading (Figure 3B) and a change in cell morphology (Figure 3D and F), characterised by 
acquisition of a condensed stellate-like morphology and loss of F-actin-stress fibres (Figure 3E), 
implying impaired actin-polymerisation. We asked if changes in cell morphology and actin 
polymerisation were mechanistically linked to regulation of EPAC1 levels. Forskolin or BAY60-
6583 stimulation of cardiac fibroblasts induced a significant reduction in the F-actin:G-actin ratio 
(Supplement Figure 3A), confirming reduced actin polymerisation in response to elevated cAMP 
signalling. This was also associated with significant reductions in phosphorylation of the ROCK 
substrate, MYPT (Supplement Figure 3B-D), indicating inhibition of RhoA-ROCK signalling. By 
contrast, cAMP-elevating stimuli did not induce any detectable morphological change, reduction 
in cell area, loss of F-actin stress fibres or a reduction in EPAC1 mRNA expression in the myocyte 
H9C2 cell line (Figure 3A-E).  In cardiac fibroblasts, stimulation with the PKA selective agonist 
6-BNZ-cAMP-AM alone induced a detectable change in morphology that was further enhanced 
by co-stimulation with 8-pCPT-2'-O-Me-cAMP-AM (Figure 3F) or I-942 (Supplement Figure 4). 
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Taken together, these data indicate that cAMP-induced down-regulation of EPAC1 is associated 
with disruption of actin-polymerisation and changes in cell morphology.  
To further test the association between cell morphology and EPAC1 expression we tested if 
washout of the cAMP stimulus would lead to restoration of cell morphology and EPAC1 mRNA 
expression levels. Forskolin stimulation for 2 hours, 8 hours or 24 hours significantly inhibited 
EPAC1 mRNA expression (Supplement Figure 5A) and induced a characteristic stellate 
morphology (Supplement Figure 5B). Importantly, levels of EPAC1 mRNA levels after a 2-hour 
forskolin stimulation followed by a 6-hour or 22-hour washout period were not significantly 
different from control levels, indicating that removal of the cAMP stimulus lead to a rapid 
restoration of EPAC1 expression. Furthermore, washout of forskolin resulted in a rapid reversal 
of the forskolin-induced morphological change (Supplement Figure 5B). 
We then asked whether actin polymerisation is required for maximal EPAC1 expression in cardiac 
fibroblast. We disrupted actin polymerisation using the Rho kinase (ROCK) inhibitor Y-27632 
and the actin binding drugs latrunculin-B (Lat-B) and cytochalasin-D (Cyto-D). Treatment of 
cardiac fibroblasts with either Y-27632, Lat-B or Cyto-D induced stellate cell morphology and a 
loss of F-actin stress fibres (Figure 4A). Treatment with Y-27632, Lat-B or Cyto-D also 
significantly reduced cell spreading (Figure 4B) and significantly inhibited EPAC1 mRNA and 
pre-spliced RNA levels, without affecting mRNA levels of the housekeeping gene 36B4 (Figure 
4C). Y-27632, Lat-B or Cyto-D stimulation also significantly reduced levels of EPAC1 protein 
(Figure 4D). 
cAMP-induced down regulation of EPAC1 impairs EPAC downstream signalling and cAMP-
induced morphological change. 
We next asked if down regulation of EPAC1 expression in response to elevated cAMP resulted in 
impaired signalling downstream of EPAC1 and impaired cAMP-induced cellular responses. Cells 
were pre-treated with forskolin for 24 hours to down regulate EPAC1 expression, which was 
confirmed by Western blotting (Supplement Figure 6A). Cells were then acutely stimulated with 
either 8-pCPT-2'-O-Me-cAMP-AM or forskolin for 30 mins and activation of Rap1 assayed. In 
non-pre-treated cells, acute stimulation with either 8-pCPT-2'-O-Me-cAMP-AM or forskolin 
resulted in an increase in Rap1GTP (active) levels (Supplement Figure 6C and D). However, in cells 
pre-treated with forskolin for 24 hours, acute stimulation with 8-pCPT-2'-O-Me-cAMP-AM or 
forskolin did not result in an increase in Rap1GTP. Furthermore, the morphological change 
(quantified as a reduction in cell spreading) induced by either forskolin or a combination of 8-
pCPT-2'-O-Me-cAMP-AM plus 6-BNZ-cAMP was significantly reduced in cells pre-treated with 
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forskolin (Supplement Figure 7 and 8). These data indicate that cAMP-induced down regulation 
of EPAC1 impairs EPAC1 down-stream signalling and cAMP-induced morphological changes. 
 
cAMP mediated inhibition of YAP-TEAD decreases EPAC1 promoter activity 
We transiently transfected cardiac fibroblasts with a secreted nano-luciferase reporter gene driven 
by the human EPAC1 proximal promoter region (EPAC1-NLUC) to determine if elevated cAMP 
and actin-cytoskeleton disruption controls EPAC1 levels at the level of transcription. Forskolin 
stimulation of EPAC1-NLUC transfected cells resulted in a significant inhibition of promoter 
activity but not of a control reporter gene driven by the TNT-minimal promoter region (Figure 
5A). Furthermore, disruption of actin-cytoskeleton polymerisation using Y-27632, latrunculin-B 
or cytochalasin-D also significantly inhibited EPAC1 promoter activity (Figure 5B). To begin to 
identify potential transcription factors that might mediate this regulation, we constructed a series 
of EPAC1 promoter truncations (-800, -600, -400 and -200 bp). Forskolin stimulation of cardiac 
fibroblasts transfected with these promoter truncations demonstrated that all promoter fragments 
were susceptible to inhibition by forskolin (Figure 5C), implying that a binding element for a 
cAMP-sensitive transcription factor mediating repression of EPAC1 transcription is located within 
the proximal 200 bp of the EPAC1 promoter. Sequence analysis of this region identified a 
conserved binding element for the transcription factor (TEAD).  Several reports have previously 
linked actin-cytoskeleton organisation to regulation of TEAD transcription factor activity [38, 40, 
49, 50].  We therefore tested if cAMP-dependent regulation of EPAC1 expression in cardiac 
fibroblasts was mediated by inhibition of TEAD activity. We initially asked if elevated cAMP or 
actin-cytoskeleton disruption inhibited TEAD activity and TEAD target gene expression. 
Stimulation of cardiac fibroblasts transfected with a synthetic TEAD reporter gene with cAMP-
elevating stimuli (forskolin, dibutyryl-cAMP or BAY60-6583) resulted in a significant inhibition 
of TEAD-dependent reporter gene activity, without significantly affecting activity of a TEAD-
independent minimal TNT-promoter (Figure 5D). Likewise, disruption of actin-cytoskeleton 
polymerisation with latrunculin-B, cytochalasin-D or Y-27632 also resulted in a significant 
inhibition of TEAD-dependent transcription (Figure 5E).  Furthermore, forskolin stimulation 
resulted in significant inhibition of mRNA levels of the classical TEAD-target genes, CTGF and 
CCN1, consistent with cAMP-mediated inhibition of TEAD activity (Figure 5F). TEAD activity 
is typically controlled by its transcriptional co-factor YES-associated protein (YAP) [51, 52]. 
Immunofluorescent staining of forskolin stimulated cardiac fibroblasts detected a significant 
reduction in nuclear and cytoplasmic levels of YAP protein (Figure 5G). Furthermore, Western 
blot analysis of total cell lysates confirmed a significant and rapid downregulation of total YAP 
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protein levels (Figure 5H and I) and an increase in the level of YAP phosphorylation at serine 172 
(Figure 5H and J) and serine 397 (Figure 5H and K). These posttranslational modifications have 
previously been associated with YAP nuclear export and degradation [52, 53]. Taken together, 
these data demonstrate that elevated cAMP and cytoskeleton disruption inhibit EPAC1 promoter 
activity and TEAD activity in cardiac fibroblasts. 
To investigate if the consensus TEAD element in the EPAC1 proximal promoter was functionally 
important for EPAC1 expression we tested if this promoter element bound TEAD1 protein and if 
it was required for maximal promoter activity. Electromobility shift assay (EMSA) analysis 
demonstrated that nuclear extracts from Myc-TEAD1 transfected fibroblasts but not control 
transfected cells produced a band of reduced mobility when incubated with a biotinylated DNA 
probe containing the wild-type EPAC1 promoter TEAD element, indicating that TEAD1 protein 
is able to bind the consensus TEAD element in the EPAC1 promoter (Figure 6A). Furthermore, 
this band was lost when a 3 base-pair mutation was introduced into the TEAD element, indicating 
sequence-specific TEAD1 interaction. In the context of a reporter gene assay, the introduction of 
this 3 bp mutation significantly inhibited EPAC1 promoter activity (Figure 6B), indicating that 
this TEAD element is required for maximal EPAC1 promoter activity in cardiac fibroblasts. To 
further confirm this, we used siRNA-mediated silencing of the TEAD co-factors, YAP and TAZ. 
Transfection of cardiac fibroblasts with siRNA targeting YAP and TAZ resulted in a strong down 
regulation of YAP and TAZ protein expression without affecting levels of GAPDH or -actin 
protein (Figure 6C). A similar down regulation of YAP and TAZ mRNA but not the housekeeping 
gene 36B4 (Figure 6F) was also detected after YAP and TAZ silencing (Figure 6D). YAP and 
TAZ silencing also significantly inhibited TEAD-reporter gene activity (Figure 6D), consistent 
with downregulation of these TEAD co-factors.  Importantly, YAP and TAZ silencing also 
significantly inhibited EPAC1 promoter activity (Figure 6E).  Furthermore, YAP and TAZ 
silencing also reduced mRNA levels of the classical TEAD-target gene CCN1 as well as 
significantly reducing EPAC1 mRNA and EPAC pre-spliced mRNA levels without affecting the 
mRNA levels of the housekeeping gene 36B4 (Figure 6F). To test the role of TEAD further, we 
transfected cardiac fibroblasts with a dominant-negative TEAD1 expression vector that expresses 
the TEAD1 DNA binding domain fused to the Drosophila engrailed transcriptional repressor 
domain (TEAD1-Eng). Expression of TEAD1-Eng significantly inhibited TEAD reporter gene 
activity without significantly affecting activity of a TEAD-independent minimal promoter reporter 
gene (Figure 6G), consistent with efficient and specific inhibition of TEAD activity. Importantly, 
expression of TEAD1-Eng also significantly inhibited EPAC1 reporter gene activity, without 
affecting activity of a minimal promoter reporter gene (Figure 6H).  
 14 
 
The formation of a YAP-TEAD complex is a critical step in activation of TEAD-dependent 
transcription. We therefore used two structurally distinct pharmacological inhibitors of the YAP-
TEAD complex, namely Verteporfin [54] and CPD3.1 [55], to further test the role of YAP-TEAD 
in EPAC1 gene expression. Treatment with Verteporfin or CPD3.1 significantly inhibited TEAD-
NLUC activity (Figure 7A). Treatment with Verteporfin or CPD3.1 also significantly inhibited 
EPAC1 promoter activity (Figure 7B) and reduced the mRNA levels of the classical TEAD-target 
genes CCN1 and CTGF as well as inhibiting levels of EPAC1 mRNA and pre-spliced mRNA 
(Figure 7C and D). Levels of the TEAD-independent housekeeping genes 36B4 or TBP were 
unaffected by either Verteporfin or CPD3.1 (Figure 7 C and D). Taken together, these data 
demonstrate that YAP/TAZ-TEAD activity is required for maximal EPAC1 gene expression in 
cardiac fibroblasts. 
YAP and TAZ are required but insufficient for EPAC1 mRNA expression 
We used adenovirus mediated over expression of constitutively-active mutants of YAP 
(YAPS127A) and TAZ (TAZ5SA) to test if YAP or TAZ activation are sufficient for EPAC1 
expression and can reverse the inhibitory effects of elevated cAMP. Adenovirus-mediated 
expression of YAPS127A completely reversed forskolin-mediated inhibition of TEAD-reporter 
activity, confirming efficient reversal of cAMP-mediated inhibition of TEAD activity (Figure 8A). 
Over expression of YAPS127A also completely reversed the forskolin-mediated inhibition of 
EPAC1 promoter activity (Figure 8B), consistent with our data demonstrating a requirement for 
YAP-TEAD activity for maximal EPAC1 expression. We therefore tested if YAPS127A over 
expression could also rescue mRNA levels of CCN1 or EPAC1 after forskolin stimulation. 
Forskolin stimulation of cells infected with a control adenovirus lacking a transgene resulted in 
significant reduction in the mRNA levels of CCN1 (Figure 8C). Moreover, this inhibition was 
completely reversed by expression of either YAPS127A or TAZ5SA, consistent with our data on 
rescue of TEAD-dependent reporter gene activity (Figure 8C). Forskolin also decreased EPAC1 
mRNA levels in control virus expressing cells (Figure 8D). However, expression of YAPS127A or 
TAZ5SA did not significantly rescue forskolin inhibition of EPAC1 mRNA levels (Figure 8D).  The 
results implied that YAP/TAZ-TEAD activity alone is insufficient for EPAC1 mRNA expression 
in cardiac fibroblasts, despite the knockdown and dominant negative data in Figures 6 and 7 
showing that YAP/TAZ-TEAD activity is required. This suggests the involvement of at least one 
additional mechanism that is required for expression of the endogenous EPAC1 gene that is not 
required for expression of the EPAC1 reporter gene activity.   
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HDAC1/3-mediated deacetylation of histone-3 lysine 27 contributes to cAMP-mediated 
inhibition of EPAC1 expression 
Plasmid-based reporter gene vectors are not typically packaged with histone proteins into 
chromatin and are largely regulated by transcription factor activity alone. However, endogenous 
genes are dependent on both transcription factor activity and histone-associated epigenetic 
regulation. We therefore considered the possibility of epigenetic control in cAMP-mediated 
repression of EPAC1 expression. Since acetylation of histone-3 at lysinse-27 is associated with an 
open chromatin conformation and active gene expression, we specifically asked whether 
epigenetic regulation of histone3 lysine-27 acetylation is necessary, in addition to YAP-TEAD 
activity, to promote EPAC1 mRNA expression and whether deacetylation mediates the repression 
of EPAC1 mRNA expression in response to elevated cAMP.  Furthermore, we investigated 
whether a requirement of histone-3 lysine-27 (H3K27) acetylation explains inability of YAP or 
TAZ over expression to rescue EPAC1 mRNA levels in forskolin stimulated cells. We used 
chromatin immunoprecipitation (ChIP) to quantify the effects of cAMP elevation on H3K27 
acetylation at the proximal EPAC1 promoter. H3K27 acetylation was detected at the EPAC1 
proximal promoter region in cultures of cardiac fibroblasts.  Moreover, stimulation with forskolin 
resulted in a significant reduction in H3K27 acetylation levels at this region (Figure 9A). In 
contrast, levels of H3K27 acetylation at the proximal promoter of HAS1, a cAMP-stimulated 
CREB target gene, were significantly increased in response to forskolin stimulation, indicating 
that forskolin induced changes in H3K27 acetylation are region specific and do not simply reflect 
global changes H3K27-acetylation levels. Importantly, the forskolin-induced reduction of H3K27-
acetylation at the EPAC1 promoter was partially but significantly reversed by pre-treatment with 
the HDAC1/3-selective HDAC inhibitor MS-275, which was not the case for CREB-target gene, 
HAS1, indicating region specific changes in H3K27-acetylation mediated by HDAC1/3 (Figure 
9B).  
We next asked whether HDAC1/3 inhibition with MS-275 would synergise with YAPS127A 
overexpression to rescue forskolin inhibition of EPAC1 mRNA. In control virus infected cells 
forskolin significantly inhibited EPAC1 mRNA levels (Figure 9C), which were not rescued by 
YAPS127A, in agreement with the data in Figure 8. By contrast, MS-275 partially antagonised the 
ability of forskolin to reduce EPAC1 mRNA levels. Importantly, however, a combination of MS-
275 and YAPS127A expression completely prevented forskolin-mediated inhibition of EPAC1 
mRNA levels, whereas expression of the housekeeping gene 36B4 remained unaffected by any of 
the treatments (Figure 9D). Hence H3K27 acetylation appeared to facilitate TEAD dependent 
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transcription of EPAC1 and cAMP elevation triggered H3K27-deacetylation as well as blocking 
TEAD activity. 
 
DISCUSSION 
The ability of cAMP to stimulate EPAC activity is well established[56] [41] [57] [58]. However, 
relatively little is known about how EPAC gene expression is regulated. In this study we 
investigated the regulation of EPAC1 gene expression in cardiac fibroblast under normal culture 
conditions and in response to cAMP-elevating stimuli. We showed that EPAC1 mRNA and 
protein expression are supported by TEAD-dependent transcription and that H3K27 acetylation is 
required for TEAD activity at the EPAC proximal promoter.  Furthermore, we demonstrate that 
elevated intracellular cAMP rapidly represses the expression of EPAC1 mRNA and protein levels 
by antagonising both processes. The first involves cAMP-induced actin-cytoskeleton 
depolymerisation and subsequent inactivation of YAP/TAZ-TEAD transcription factor activity. 
The second involves cAMP-mediated deacetylation of H3K27 at the EPAC1 proximal promoter 
region. Repression of EPAC1 expression via these mechanisms attenuates EPAC1 signalling and 
EPAC1-dependent morphological changes in response to subsequent cAMP-elevating stimuli. 
Together, these mechanisms constitute a newly discovered mechanism of crosstalk that represses 
EPAC1 expression in response to cAMP elevating stimuli and is important in controlling cellular 
responses to cAMP elevating stimuli (Figure 10). 
In detail, cAMP elevation in cardiac fibroblasts using either forskolin, cAMP analogues or 
physiological agonists of the adenosine A2B receptor rapidly represses EPAC1 expression in 
cardiac fibroblasts. Selective activation of either EPAC or PKA alone inhibited EPAC1 mRNA 
expression, with simultaneous activation of PKA and EPAC acting additively. Interestingly, PKA 
activation was more effective than EPAC activation at down regulating EPAC1 expression, 
suggesting a dominant role for PKA-mediated negative crosstalk in controlling EPAC1 
expression. Negative crosstalk between PKA and EPAC have been reported previously. For 
example, PKA can antagonise EPAC induced phosphorylation of AKT [59]. PKA can reduce the 
ability of the EPAC effector protein Rap1 to regulate angiogenesis [60]. PKA can also regulate 
cAMP-dependent activation of EPAC by controlling the availability of cAMP via 
phosphodiesterases [61]. Our new data now demonstrate that PKA and EPAC-activation both play 
an important role in regulating EPAC1 gene expression in cardiac fibroblasts. 
Repression of EPAC1 expression in cardiac fibroblasts in response to elevated cAMP is associated 
with acquisition of a condensed ‘stellate’ shaped cell morphology characterised by a condensed 
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cytoplasm, extended membrane protrusion and loss of F-actin stress fibres. Similar cAMP-induced 
morphological changes and inhibition of actin-polymerisation have been described in some other 
cell types, including smooth muscle cells[41, 42, 62, 63], astrocytes [64] and mesenchymal stem 
cells [65]. Interestingly, in cardiac fibroblasts, the magnitude of the stellate morphology and 
reduction in actin-cytoskeleton polymerisation induced by activation of PKA and EPAC mirrors 
the repression of EPAC1 gene expression. However, these cAMP-induced stellate morphological 
changes and inhibition of actin polymerisation are cell-type specific. Although elevated cAMP 
induces rapid and pronounced actin-cytoskeleton disruption in cardiac fibroblasts and smooth 
muscle cells[41, 48, 66], this does not occur in endothelial cells, where cAMP signalling promotes 
cortical actin polymerisation via PKA and EPAC activation [6, 67-69]. We have shown that cAMP 
signalling does not induce morphological changes or inhibition of actin polymerisation in the 
H9C2 cardiac myocyte cell line. Importantly, EPAC1 expression is not repressed by cAMP-
elevating stimuli in these cells, implying that repression of EPAC1 expression is, at least in part, 
mediated by these changes in the actin-cytoskeleton polymerisation status. Consistent with this, 
we demonstrated that disruption of actin-polymerisation, using the ROCK inhibitor Y-26732, or 
directly with the actin-binding drugs cytochalasin-D or latrunculin-B, also repress EPAC1 
expression in cardiac fibroblasts. To our knowledge this is the first time that EPAC1 expression 
has been linked to actin-cytoskeleton remodelling, although previous reports have linked EPAC1 
localisation and function to actin organisation. For example, EPAC1 interaction with the actin 
binding ERM (Ezrin, Radixin and Moesin) proteins has been implicated in localisation of EPAC1 
to the plasma membrane cortical actin, where it participates in cAMP-dependent regulation of cell 
proliferation and cell spreading [70-72]. Our new data now establish the existence of a novel 
negative crosstalk mechanism where PKA cooperates with EPAC activity to induce actin-
cytoskeleton remodelling, which contributes to repression of EPAC1 gene expression. 
Several signals have been linked to modulation of EPAC1 expression. TGF- stimulation can have 
stimulatory or repressive effects on EPAC1 expression in cardiac fibroblasts or myofibroblasts 
respectively [5].  Prostaglandin E2 stimulation reduces EPAC1 protein expression in carbon 
tetrachloride-induced liver fibrosis in mice [73]. β-adrenoceptor (AR) receptor activation with 
isoproterenol increases EPAC1 expression in atrial fibroblasts [14]. However, the underlying 
mechanisms that control EPAC1 gene expression in response to physiological signals is unknown. 
Here we describe a feedback mechanism that represses EPAC1 gene transcription in response to 
elevated cAMP. For example, we show that levels of pre-spliced EPAC mRNA, a surrogate 
measure of transcriptional rate [46], are rapidly down regulated by cAMP-elevating stimuli. 
Furthermore, the activity of the proximal EPAC1 promoter region is also repressed by these 
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stimuli, consistent with transcriptional mode of repression. Analysis of the EPAC1 proximal 
promoter region identified a conserved binding element for the TEAD transcription factors. 
Importantly, TEAD transcription factor activity is known to be dependent on actin-cytoskeleton 
organisation and integrity [38] [74], consistent with our data showing that maximal EPAC1 
expression is also dependent on actin-cytoskeleton. We show that elevated cAMP represses TEAD 
activity in cardiac fibroblasts and this is associated with increased phosphorylation of the TEAD 
co-factor YAP and a reduced levels of YAP protein in the nucleus and cytoplasm.  We demonstrate 
that maximal EPAC1 expression is dependent on YAP/TAZ-mediated TEAD activity. For 
example, inhibition of TEAD activity using silencing of the TEAD co-factors YAP and TAZ, 
overexpression of a dominant-negative TEAD mutant or inhibition of TEAD activity using two 
chemically distinct pharmacological inhibitors all significantly inhibited EPAC1 transcription. To 
our knowledge, this is the first time that EPAC1 expression has been linked to cytoskeleton 
integrity and YAP/TAZ-TEAD activity.  
Although we demonstrate a clear requirement for YAP/TAZ-TEAD activity for EPAC1 
expression, our data also demonstrate that activation of this mechanism in isolation, via expression 
of constitutively active YAP or TAZ mutants, is insufficient for expression of EPAC1 mRNA, 
highlighting the involvement of additional mechanisms. While expression of constitutively active 
YAP or TAZ were able to completely reverse cAMP-dependent repression of the EPAC1 promoter 
driven reporter gene activity, they were not able to reverse the inhibition of EPAC1 mRNA levels. 
Since plasmid-based reporter gene vectors are not typically packaged with histone proteins into 
chromatin, we reasoned that histone-associated epigenetic regulation was also involved in cAMP-
mediated repression of EPAC1 expression. Consistent with this, we detected a significant decrease 
in histone-3 lysine-27 acetylation (H3K27Ac), an epigenetic modification associated with active 
transcription[75], at the proximal EPAC1 promoter region in cardiac fibroblasts stimulated with 
forskolin. Our data suggest that this loss of H3K27Ac was mediated by HDAC1 or HDCA3, since 
loss of H3K27Ac at the EPAC1 promoter in response to forskolin stimulation was reversed by the 
HDAC1/3 selective inhibitor MS-275. Importantly, our data demonstrates that this epigenetic 
modification acts cooperatively with inhibition of YAP/TAZ-TEAD to mediated cAMP-
dependent repression of EPAC1 expression. For example, HDAC inhibition or expression of 
constitutively active YAP/TAZ alone only partially rescued EPAC1 mRNA expression in 
forskolin-stimulated cells, whereas HDAC inhibition together with constitutively-active 
YAP/TAZ fully reverse the inhibitory effects of forskolin.  
Taken together, our data demonstrate that inhibition of YAP/TAZ-TEAD and HDAC1/3 -
mediated H3K27 deacetylation underlies the repression of EPAC1 expression in cardiac 
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fibroblasts in response to cAMP-elevating stimuli. We suggest that this mechanism represents a 
novel mechanism of cross talk that controls EPAC1 signalling. Such loops that feed an inverted 
output signal back to the input are found in nearly all known signalling pathways, serving to 
maintain normal physiological signalling homeostasis and allowing for adaptive cellular responses 
to a persistent signal. Down regulation of EPAC1 expression via the control loop we describe here 
is likely to be important in the temporal regulation of EPAC1 signalling, generating transient 
signals responses in prolonged cAMP elevation. Selective down regulation of EPAC1 but not PKA 
catalytic subunits suggests that subsequent cAMP signalling may also be adapted towards PKA-
specific responses.  
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FIGURES 
Figure 1 
 
Figure 1: Adenosine A2B activation and elevated cAMP inhibits EPAC1 expression in cardiac 
fibroblasts 
Serum-starved CF were stimulated with BAY60-6583 (5 µg/mL; A-B), forskolin (25 µM; C-D) 
and dibutyryl-cAMP (200 µM; E-F) for 2 to 8 hours. Total RNA was extracted and analysed by 
qRT-PCR for fully spliced and pre-spliced EPAC1 and 36B4 mRNA (A, C and E). Total cell 
lysates were analysed for the levels of EPAC1 and GAPDH protein by Western blotting and 
densitometric analysis (B, D, F). ANOVA with Student Newman Keul’s post-test. Data are 
expressed as mean ±SD (n = 3). *, ** and *** indicate p<0.05, p<0.01 and p<0.001 respectively.  
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: PKA and EPAC activity co-ordinately regulate EPAC1 expression in cardiac 
fibroblasts 
Serum-starved CF were stimulated forskolin (25 µM) alone or in combination with either H89 (10 
µM) or ESI-09 (10 µM), as indicated, for two hours (A) or with 6-BNZ-cAMP-AM (6-BNZ-AM; 
20 µM), I-942 (100 µM) or 8-pCPT-2'-O-Me-cAMP-AM (8-CPT-AM, 20 µM) as indicated, for 8 
hours (B). Total RNA was extracted and analysed for EPAC1 mRNA, pre-spliced EPAC1 mRNA 
and 36B4 mRNA by qRT-PCR (A; n=5, B and C; n=3). Total cell lysates were analysed for 
EPAC1 and GAPDH protein levels by Western blotting and densitometric analysis (D; n=4). Data 
are expressed as mean ±SD and analysed by ANOVA with Student Newman Keul’s post-test. (n 
= 3). *, ** and *** indicate p<0.05, p<0.01 and p<0.001 respectively.  
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Figure 3 
 
Figure 3: Inhibition of EPAC1 expression by cAMP is associated with actin cytoskeleton 
remodelling and changes in cell morphology 
Serum-starved CF and H9C2 cells were stimulated with forskolin (25 µM) or dibutyryl-cAMP 
(200 µM) for 8 hours, as indicated. Total RNA was extracted and analysed for EPAC1 mRNA by 
qRT-PCR (A). Cell spreading (B and C) and cell morphology (D) was analysed by phase contrast 
microscopy. F-actin stress fibres were detected by phalloidin staining (E). Serum-starved CF were 
stimulated with 6-BNZ-cAMP-AM (6-BNZ-AM, 20 µM) and 8-pCPT-2'-O-Me-cAMP-AM (8-
CPT-AM, 20 µM), alone or in combination and cell morphology assessed by phase contrast 
microscopy (F). Data are expressed as mean ±SD and analysed by ANOVA with Student Newman 
Keul’s post-test. (n = 3). ** indicates p<0.01.  
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Figure 4 
 
 
Figure 4: Actin cytoskeleton disruption inhibits EPAC1 expression 
Serum-starved CF were stimulated with 10 µM Y-27632, 2 µM cytochalasin-D (Cyto-D) or 0.5 
ug/mL latrunculin-B (Lat-B) for 8 hours. Cell morphology and F-actin stress fibres were analysed 
by phase contrast microscopy and phalloidin staining, respectively (A). Cell area was quantified 
by image analysis of phase contrast images (B). Total RNA was extracted and analysed for EPAC1 
mRNA, pre-spliced EPAC1 mRNA and 36B4 mRNA by qRT-PCR (C; n=3). Total cell lysates 
were analysed for EPAC1 and GAPDH protein levels by Western blotting and densitometric 
analysis (D; n=5). Data are expressed as mean ±SD and analysed by ANOVA with Student 
Newman Keul’s post-test. *, ** and *** indicate p<0.05, p<0.01 and p<0.001 respectively.  
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Figure 5 
 
Figure 5: Elevated cAMP and inhibition of actin polymerisation reduces EPAC1 promoter 
activity and TEAD activity in cardiac fibroblasts 
Cardiac fibroblasts were transfected with EPAC1-NLUC reporter (A and B) and stimulated with 
25 µM forskolin, 10 µM Y-27632, 2 µM Cyto-D or 0.5 µg/mL Lat-B for 8 hours. Cells were 
transfected with a NLUC reporter vector controlled by the indicated EPAC1 promoter truncations 
or a minimal promoter, as indicated, and NLUC activity assayed 24 hours later (C). Cells were 
transfected with a TEAD-LUC reporter or minimal promoter-LUC reporter vector as indicated 
and stimulated with 5 µg/mL BAY65-6085, 25 µM forskolin, 200 µM db-cAMP and luciferase 
activity quantified after 8 hours (D). Cardiac fibroblasts were transfected with a TEAD-LUC 
reporter vector and stimulated with 10 µM Y-27632, 2 µM Cyto-D and 0.5 µg/ml Lat-B and 
luciferase activity was quantified after 8 hours (E). Cardiac fibroblasts were stimulated with 25 
µM forskolin for 2 and 8 hours. Total RNA was extracted and analysed for CCN1 mRNA, pre-
spliced CCN1 RNA, CTGF mRNA, pre-spliced CTGF RNA and 36B4 mRNA levels. CF were 
stimulated with 25 µM forskolin for 2 hours (G) or indicated times (H-K).  Nuclear and 
cytoplasmic YAP levels were quantified by image analysis of immunofluorescent micrographs 
(G). Total cellular YAP, phospho-YAPS127, phospho-YAP S397 were quantified by Western 
blotting (H) and densitometric analysis (I-K). Data are expressed as mean ±SD and analysed by 
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ANOVA with Student Newman Keul’s post-test. *, ** and *** indicate p<0.05, p<0.01 and 
p<0.001 respectively.  
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Figure 6 
 
Figure 6: YAP/TAZ-TEAD activity is required for maximal EPAC1 expression 
Electromobility shift assay (EMSA) analysis of binding of TEAD protein from nuclear extracts 
from control or myc-TEAD1 transfected cardiac fibroblasts to DNA probes containing either the 
wild-type or mutated TEAD element from the EPAC1 proximal promoter (A). Cardiac fibroblasts 
were transfected with a secreted nanoluciferase reporter (NLUC) gene plasmid under the control 
of either the wild-type EPAC1 promoter or the EPAC1 promoter containing a mutated TEAD 
element. Secreted NLUC activity was quantified 24 hours after transient transfection (B). Cardiac 
fibroblasts were transfected with siRNA targeting YAP and TAZ (siYAP/TAZ) or non-targeting 
control siRNA (siControl), together with TEAD-LUC or EPAC1-NLUC reporter plasmids. Total 
cell lysates were analysed for protein levels of YAP, TAZ, GAPDH or -ACTIN by Western 
blotting (C) and reporter gene activity quantified (D and E).  Total RNA was extracted and 
analysed for the mRNA levels of YAP, TAZ, EPAC1, pre-spliced EPAC1 mRNA, CCN1 and 
36B4 using RT-qPCR (F). Cardiac fibroblasts were transfected with TEAD-LUC (G), EPAC1-
NLUC (H) or a minimal promoter reporter (G and H), together with either an empty expression 
vector lacking a transgene (Control) or a dominant-negative TEAD expression vector, as indicated 
(F and G). Reporter gene activity was quantified 24 hours after transfection. Data are expressed 
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as mean ±SD and analysed by paired Students t-test (B, D, E, G, H) or ANOVA with Student 
Newman Keul’s post-test (F). *, ** and *** indicate p<0.05, p<0.01 and p<0.001 respectively.  
 
Figure 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Pharmacological TEAD inhibition reduces EPAC1 expression 
Cardiac fibroblasts were transfected with TEAD-LUC reporter (A) or EPAC1-NLUC reporter (B) 
and stimulated with either 60 µM CPD 3.1 or 10 µM verteporfin. Reporter gene activity was 
quantified 24 hours after transfection. Cardiac fibroblasts were stimulated with 60 µM CPD3.1 for 
8 or 18 hours (C) or 10 µM Verteporfin (D) and total RNA was extracted and analysed for the 
mRNA levels of EPAC1, pre-spliced EPAC1, CCN1, CTGF, TBP and 36B4 mRNA by RT-qPCR. 
Data are expressed as mean ±SD and analysed by ANOVA with Student Newman Keul’s post-
test. *, ** and *** indicate p<0.05, p<0.01 and p<0.001 respectively.  
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Figure 8 
 
Figure 8: YAP and TAZ are insufficient for EPAC1 mRNA expression 
Cardiac fibroblasts were transfected with TEAD-LUC (A) or EPAC-NLUC (B) reporter gene 
plasmids. The next day, cells were infected with either a control adenovirus (Ad:Control) or 
adenovirus expressing constitutively-active YAP or TAZ, as indicated (A-D). Cells were then 
stimulated with 25 µM forskolin for 8 hours and reporter gene activity quantified (A and B) or 
total RNA analysed by qRT-PCR for EPAC1 mRNA or CCN1 mRNA levels as indicated. (C and 
D). Data are expressed as mean ±SD and analysed by ANOVA with Student Newman Keul’s post-
test. *, ** and *** indicate p<0.05, p<0.01 and p<0.001 respectively.  
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Figure 9 
 
 
Figure 9: HDAC1/3 mediated deacetylation of histone-3 lysine-27 contributes to cAMP-
mediated inhibition of EPAC1 mRNA expression 
Cardiac fibroblasts were treated with 5 µM MS275 for 18 hours followed by stimulation with 25 
µM forskolin for a further 2 hours (A and B). Cells were fixed and chromatin extracted and 
analysed for H3K27Ac at the proximal EPAC1 (A) or HAS1 (B) promoter regions. Cells were 
infected with control adenovirus (Ad:Control) or adenovirus expressing constitutively active YAP 
(Ad:YAP) (C and D). The next day, cells were treated with 5 µM MS275 for 18 hours followed 
by stimulation with 25 µM forskolin for a further 2 hours. Total RNA was extracted and analysed 
by RT-qPCR for EPAC1 (C) or 36B4 (D) mRNA levels. Data are expressed as mean ±SD and 
analysed by ANOVA with Student Newman Keul’s post-test. ** and *** indicate, p<0.01 and 
p<0.001 respectively.  
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Figure 10 
 
 
Figure 10: Proposed mechanism underlying cAMP-dependent repression of EPAC1 
expression. 
In cardiac fibroblast with low levels of cAMP, PKA and EPAC activity are low and RhoA/ROCK 
activity is high. This results in actin polymerisation and nuclear translocation of YAP/TAZ. 
YAP/TAZ increase activity of TEAD transcription factors, which act via a conserved TEAD 
binding element in the proximal EPAC1 promoter to induce EPAC1 gene expression. Elevated 
cAMP levels activate PKA and EPAC1, which cooperate to inhibit RhoA/ROCK-mediated actin 
polymerisation, resulting in reduced actin polymerisation and acquisition of a stellate cell 
morphology. This induces nuclear export of YAP/TAZ, which in turn reduces TEAD activity. 
Elevated cAMP also induces a HDAC1/3-mediated reduction in histone H3K27 acetylation at the 
proximal EPAC1 promoter. The reduction in TEAD activity together with the reduction in histone 
H3K27 acetylation inhibits EPAC1 gene expression. 
 
 
 
 
 
 
 
 
 
